Tradestie Institutional Equity Comparison Engine

IONS vs CRNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRNX Overall Edge

CRNX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crinetics Pharmaceuticals, Inc. (CRNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus CRNX at N/M Forward P/E and -527.4% operating margin (+2336.3% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against CRNX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IONS
IONS 90.9x vs CRNX N/M Fwd P/E
Growth & Margin Winner CRNX
Op Margin -58.8% vs -527.4% ยท YoY +54.9% vs +2336.3%
Momentum & Technical Winner CRNX
1Y -59.1% vs +177.2% ยท 52W Pos 2% vs 100%
Options & Structure Winner CRNX
BREAKDOWN (17th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
CRNX NASDAQ
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
$84.95
+0.13% 1D
Market Cap $9.0B
1M Return +1.71%
1Y Return +177.16%
Forward P/E N/M
Unified AI Score
46.8 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 60.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% CRNX +177.16% Spread: +118.61 pp (CRNX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IONS Revenue CRNX Revenue IONS Op. Margin CRNX Op. Margin Margin Edge
FY2018 $600M $0M -10.2% -1182.5% IONS
FY2019 $1.12B $0M 32.6% -4512.3% IONS
FY2020 $730M $0M -23.6% -105567.6% IONS
FY2021 $810M N/A -3.7% N/A IONS
FY2022 $590M N/A -69.8% N/A IONS
FY2023 $790M $0M -44.9% -5547.2% IONS
FY2024 $710M $0M -67.4% -32613.5% IONS
FY2025 $940M $10M -40.4% -6714.8% IONS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (4) vs CRNX (6)
Institutional Metric IONS CRNX Criterion Row Winner
Market Capitalization Scale $4.7B $9.0B Larger Scale CRNX
Trailing P/E Ratio Valuation 90.9x N/M Lower Multiple IONS
Forward P/E Ratio Valuation 90.9x N/M Lower Multiple IONS
Revenue Growth (YoY) Growth +54.9% +2336.3% Higher Growth CRNX
Operating Margin (TTM) Profitability -58.8% -527.4% Higher Margin IONS
Net Profit Margin Profitability -56.9% 0.0% Higher Margin CRNX
Return on Equity (ROE) Capital Efficiency -108.0% -42.4% Higher ROE CRNX
52-Week Range Position Momentum 2% ($27โ€“$87) 100% ($30โ€“$85) Stronger Trend CRNX
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 0.29ฮฒ ยท 2% Vol Lower Realized Risk CRNX
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 46.8 / 100 (HOLD) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs CRNX Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRNX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live CRNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor CRNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.